You have read all your free articles, to continue reading subscribe to read the rest of this content.
The U.S. Food and Drug Administration (FDA) has given clearance to start the company's phase III clinical study CONCLUDE in the United States. The study will evaluate the efficacy and safety of the TLR9 agonist cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis. Already a subscriber Login…
The Board of Directors of BioInvent International has resolved to issue a directed share issue to Swedish and international institutional investors. Investors in the Directed Share Issue are a number of Swedish and international investors, including new investors such as HBM Healthcare InvestmentAlready a subscriber Login You have read all…
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes. The approval of Rybelsus in JapaAlready a subscriber Login…
Moberg Pharma announces that the company has decided to issue a five-year senior unsecured bond loan in the amount of SEK 300 million with maturity on January 29th, 2021. The bond loan will give a floating rate coupon of Stibor 3m + 6.00% and have a total framework amount of SEK…
